Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial.
Latest Information Update: 03 Jun 2025
At a glance
- Drugs Velusetrag (Primary)
- Indications Intestinal pseudo-obstruction
- Focus Therapeutic Use
- Sponsors Alfasigma
Most Recent Events
- 25 May 2025 Status changed from active, no longer recruiting to completed.
- 06 Sep 2023 This trial has been completed in Italy (Global end date: 12 Apr 2023).
- 02 Feb 2023 Status changed from recruiting to active, no longer recruiting.